SET like protein (SETSIP)

SET like protein (SETSIP) is a processed pseudogene in Homo sapiens, sharing high sequence homology to the functional SET oncoprotein but lacking established catalytic activity or direct clinical relevance as a drug target[1][3][5][7]. SETSIP encodes a protein (or noncoding RNA) with reported transcriptional activator properties involved in early stages of somatic cell reprogramming, including promoting differentiation of fibroblasts into endothelial cells[3][5]. However, unlike the canonical SET protein, which is implicated in cell cycle regulation, apoptosis, and oncogenesis[1], SETSIP is primarily classified as a transcriptionally active pseudogene[3][4][5][7]. There is no evidence of its use as a therapeutic target, nor documented drug interactions, biomarkers, or safety concerns in the literature. Most scientific resources and databases (UniProt, GeneCards, Human Protein Atlas) treat SETSIP as a noncanonical regulatory entity with uncertain biological and disease relevance in humans[3][5][7]. Key clarifications: - While SET-like protein may be transcribed and exhibit limited activity, it is not considered a therapeutic target by standard pharmacological or biochemical definitions[1][3][5][7]. - Its parent gene, SET, is functionally significant in cancer biology and cell regulation[1], but SETSIP itself does not inherit these roles. - No evidence supports clinical targeting, interactome mapping, or biomarker utility for SETSIP. If structured targeting information is required, focus should shift to the canonical SET nuclear oncogene protein rather than SET like protein (SETSIP), which remains a nonfunctional or weakly functional pseudogene according to current science[1][3][5][7][2].

Other names

SETSIPSETP18SET pseudogene protein 18SET similar proteinSimilar to SET translocation proteinprotein SETSIPSET nuclear oncogene pseudogeneSET pseudogene 18